Dexcom stock forecast 2025 for growth investors

For growth investors, Dexcom stock forecast 2025 is supported by continued expansion in subscription models, creating steady ARR (Annual Recurring Revenue). DexCom has announced a leadership transition. Kevin R. Sayer will take a temporary medical leave effective September 14, 2025. Jacob S. Leach has been appointed as interim principal executive officer and will assume the role of CEO following Sayer’s planned retirement on January 1, 2026. Sign up for free newsletters and get more CNBC delivered to your inbox Healthcare ETF flows could bolster Dexcom stock forecast 2025, as DXCM remains a core holding in growth-focused portfolios seeking exposure to medtech innovation.